One of the less endearing, if not outright annoying, traits of those who
make up Wall Street is their tendency to harp on whatever a company
doesn't have at the moment. In the case of Big Pharma, good current
quarterly results are often waved off with skepticism about generic
competition and/or the pipeline. For GlaxoSmithKline (GSK)
it looks like the reverse is true. Forget the solid pipeline and good
recent Phase 3 results, it's this quarter's bad performance that somehow
proves Glaxo isn't a good company.
Please read more here:
GlaxoSmithKline's R&D Is Delivering, But The Street's Not Buying
No comments:
Post a Comment